Drug Trial Radar · NCT05715320
Study of CM310 Injection in Subjects With Moderate-to-Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Oct 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
160
Actual
Start
Mar 10, 2023
Primary completion
Jul 18, 2024
Study completion Jul 18, 2024
Sponsor
- Lead sponsor
- Keymed Biosciences Co.LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multi-center, randomized, double-blind, parallel controlled phase 2 study, aimed at evaluating the efficacy and safety of CM310 in the treatment of patients with moderate-to-severe atopic dermatitis, and observing Pharmacokinetics characteristics, Pharmacodynamics effects and immunogenicity.
Conditions
- Atopic Dermatitis
Interventions
CM310Biological
IL-4Rα monoclonal antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects achieving EASI-75Time frame: up to week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.